Please login to the form below

Not currently logged in

J&J inks $1bn deal with US for coronavirus vaccine

Agreement includes manufacturing and delivery of 100 million doses


Johnson & Johnson has reached an agreement with the US government for 100 million doses of its investigational COVID-19 vaccine.

Under the terms of the deal, the US’ Biomedical Advanced Research and Development Authority (BARDA) and the US Department of Defense are committing $1bn for the first 100 million doses. The US government also has the option to purchase an additional 200 million doses under a subsequent agreement.

J&J’s Ad26.COV2.S vaccine recently demonstrated promising pre-clinical results in initial animal studies, with the vaccine inducing a robust immune response in non-human primates and successfully preventing subsequent infection. The vaccine also provided complete or near-complete protection from the SARS-CoV-2 virus, which causes COVID-19.

The pharma giant has already initiated a phase 1/2a human clinical trial of the vaccine in the US and Belgium, which is evaluating both one- and two-dose regimens of Ad26.COV2.S in over 1,000 healthy adults aged 18 to 55 years, as well as in adults aged 65 and over.

If the vaccine proves effective in a large cohort of participants, J&J hopes to start a phase 3 trial of a single dose versus placebo in September along with a parallel phase 3 study of a two-dose regimen versus placebo.

“J&J’s global team of experts has worked tirelessly alongside BARDA and scientific partners to pursue a SARS-CoV-2 vaccine that can help to stop the spread of COVID-19,” said Paul Stoffels, vice chairman of the executive committee and chief scientific officer at J&J.

“We greatly appreciate the US government's confidence in, and support for, our R&D platform and efforts and the scalability of our vaccine technology. We are scaling up production in the US and worldwide to deliver a SARS-CoV-2 vaccine for emergency use,” he added.

The US has already signed a number of agreements with a range of companies currently developing COVID-19 vaccines. This includes a deal with Sanofi/GlaxoSmithKline for 100 million doses, as well as a $1.95bn deal for 100 million doses of Pfizer/BioNTech’s candidate and similar deals with Novavax and AstraZeneca/Oxford University.

J&J has committed to providing its vaccine on a not-for-profit basis, whereas some of its competitors are seeking to recoup on their investments by pricing their candidates for profit.

That includes vaccine frontrunner Moderna, which said in a recent quarterly earnings call that it has signed agreements for its candidate at between $32-$37 per dose, with two doses required for a full course.

Meanwhile, Pfizer/BioNTech has priced its vaccine at $19.50 per shot – $39 per course – following its $1.95bn supply deal with the US government earlier this month. In contrast, AZ/Oxford have priced their candidate at a cost price of just €2.5 ($2.96) per unit.

Article by
Lucy Parsons

6th August 2020

From: Sales



COVID-19 Updates and Daily News

Featured jobs


Add my company

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....